Haleon plc has announced that it is evolving its operating model in support of its Win as One strategy to drive its growth, productivity and culture agenda, as set out at its Capital Markets Day in May 2025. These changes are expected to be implemented by mid-2026. Haleon is creating six Operating Units (OUs) to enable the Company to capitalise on the significant growth opportunities in its key markets, with each OU responsible for delivering business performance through the execution of Haleon's category strategies.
The current EMEA & LatAm region will be separated into three constituent OUs: Latin America (LatAm), Middle East and Africa (MEA) and Europe. Recognising the strength of Haleon's business in India Subcontinent (ISC) and the opportunities for growth, ISC will become its own OU, separate from Asia Pacific. Haleon's North America OU remains unchanged.
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows:
- oral health products (29.5%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.;
- Pain relief medicines (22.8%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.;
- medicines for digestive health (17.7%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.;
- vitamins, minerals and food supplements (15.1%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.
- respiratory medicines (14.9%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.;
Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.2%), North America (36%), and Asia/Pacific (22.8%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
